Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04345614 · ClinicalTrials.gov registry record · Phase 2

A Study of Auxora in Patients With Severe COVID-19 Pneumonia

A Phase 2 study of Pneumonia, sponsored by CalciMedica.

Completed
Registry status
Phase 2
Development phase
314
Enrollment target
17
Study locations

NCT04345614: Completed Phase 2 study of Pneumonia, sponsored by CalciMedica.

NCT04345614 is a Phase 2 study of Pneumonia that has completed, run by CalciMedica. The registered enrollment target is 314 participants, below the 4,513-participant average among 47 other Pneumonia trials with a reported enrollment target (93% lower). The trial reports 17 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04345614, a Phase 2 study of Pneumonia, has completed, sponsored by CalciMedica.

COMPLETED
Registry status
Phase 2
Development phase
314 participants
Enrollment target
17
Study locations

Study Summary

Part 1 of this trial enrolled 30 patients to receive Auxora (formerly CM4620) in a 2:1 randomized, open label trial of patients with severe and critical COVID-19 pneumonia. Part 2 of this study randomized 284 patients and was a randomized, double blind, placebo-controlled (RCT) study that evaluated the efficacy, safety, and the pharmacokinetic profile of Auxora in patients with severe COVID-19 pneumonia. The number of patients with an imputed PaO2/FiO2 \>200 randomized into the study was capped at 26. Another 258 patients with a PaO2/FiO2 ≤200 were enrolled. Patients with an estimated PaO2/FiO2 of 75-200 were stratified to ensure balanced randomization between the Auxora and placebo arms. Subgroup analyses were performed to explore how time to recovery is influenced by baseline variables and to evaluate the treatment effect at different levels of each of these variables. The dose of Auxora was 2.0 mg/kg (1.25 mL/kg) administered at 0 hour, and then 1.6 mg/kg (1 mL/kg) at 24 hours and 1.6 mg/kg (1 mL/kg) at 48 hours from the SFISD. The dose of placebo was 1.25 mL/kg administered at 0 hour and then 1 mL/kg at 24 hours and 1 mL/kg at 48 hours from the SFISD. Remdesivir, corticosteroids and convalescent plasma were allowed. The infusion of Auxora / Placebo started within 12 hours from the time the patient or LAR provided informed consent. Efficacy analyses will be presented by treatment group (Auxora vs Placebo) based on the Efficacy Analysis Set of the imputed PaO2/FiO2 ≤200 subgroup, except where it is specified otherwise. The statistical analysis approach was designed to assess the significance of the primary and first secondary endpoint using the Benjamini and Hochberg method to control the overall trial level alpha level.

Primary Outcome

Defined as the number of days hospitalized but not requiring supplemental oxygen or ongoing medical care, or; discharged and requiring supplemental oxygen, or; discharged, not requiring supplemental oxygen.

Conditions Studied

Pneumonia

Interventions

  • DRUG Auxora (Part 1)
  • DRUG Standard of Care (Part 1)
  • DRUG Auxora (Part 2)
  • DRUG Placebo (Part 2)

Study Locations (17)

California

  • Long Beach Memorial - Long Beach
  • University of Southern California / LA County - Los Angeles
  • Sharp Memorial San Diego - San Diego

Texas

  • Texas Tech University Medical Center - El Paso
  • John Peter Smith Hospital - Fort Worth
  • Houston Methodist Hospital - Houston

Michigan

  • Henry Ford Hospital - Detroit
  • Sinai Grace - Detroit

Minnesota

  • Methodist Hospital - Saint Louis Park
  • Regions Hospital - Saint Paul

Colorado

  • National Jewish Health / St. Joseph's Hospital - Denver

Illinois

  • Northwestern University - Chicago

Louisiana

  • Baton Rouge General - Baton Rouge

Maine

  • Maine Medical Center - Portland

Trial Details

FieldValue
Enrollment Target 314 participants
Start Date 2020-04-08
Est. Completion 2021-07-30
Phase Phase 2
CalciMedica

6 total trials

What the finished NCT04345614 record still lists

NCT04345614 is an interventional study that assigns participants to a tested intervention. The registered 314 participants enrollment target is mid-sized for trials with a published cap, below the 4,513-participant average among 47 other Pneumonia trials with a reported enrollment target (93% lower).

The record links to 1 condition, with Pneumonia appearing as the primary indexed condition, and to 4 interventions - of which Auxora (Part 1) is the first listed.

NCT04345614 lists 17 locations in 11 states (California, Texas, Michigan).

Frequently Asked Questions

What is clinical trial NCT04345614 about?

NCT04345614 is a clinical study titled "A Study of Auxora in Patients With Severe COVID-19 Pneumonia". Part 1 of this trial enrolled 30 patients to receive Auxora (formerly CM4620) in a 2:1 randomized, open label trial of patients with severe and critical COVID-19 pneumonia. Part 2 of this study randomized 284 patients and was a randomized, double blind, placebo-controlled (RCT) study that evaluated ...

What is the current status of trial NCT04345614?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 314 participants. The study started on 2020-04-08. Estimated completion is 2021-07-30.

What conditions does trial NCT04345614 study?

This clinical trial studies the following conditions: Pneumonia.

What interventions are being tested in trial NCT04345614?

The interventions under investigation include: Auxora (Part 1) (DRUG), Standard of Care (Part 1) (DRUG), Auxora (Part 2) (DRUG), Placebo (Part 2) (DRUG).

Who is sponsoring clinical trial NCT04345614?

This trial is sponsored by CalciMedica, which has 6 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04345614 being conducted?

This trial has 17 study locations across California, Colorado, Illinois, Louisiana, Maine. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Pneumonia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04345614's enrollment target sits among peer trials

314 17th of 47 higher than 31 of 47 other Pneumonia trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Pneumonia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03866382 · 314 participants · Phase 2

    Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

  • NCT04500756 · 314 participants · Phase 2

    Limiting AAA With Metformin (LIMIT) Trial

  • NCT06167746 · 314 participants · Phase 3

    iCare4Me Transitions

  • NCT06883097 · 314 participants · NA

    Quitting Matters Human Immunodeficiency Virus Hybrid Trial

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT04345614, the US trial registry maintained by the National Library of Medicine. NCT04345614 (mid enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.